Structural optimization of CHI3L1 inhibitors with improved pharmacokinetics and functional activity in 3D glioblastoma models.
Chitinase-3-like protein 1 (CHI3L1) is a key driver of glioblastoma (GBM) progression and an emerging therapeutic target. Building on the CHI3L1 inhibitor 11 g, we optimised the scaffold through medicinal chemistry to assess structure-property relationships and improve pharmacokinetics. Using microscale thermophoresis (MST) and computational studies, we validated 10p, which exhibits a CHI3L1 binding affinity (Kd) of 13.22 µM. Notably, 10p overcomes previous developability hurdles by achieving a kinetic solubility of 758 µM, a five-fold improvement over 11 g. It further demonstrates high metabolic stability across species and no hERG inhibition. In 3D GBM spheroid models, 10p significantly reduced tumour viability, mass, and migration, exceeding the efficacy of prior analogues. Collectively, these findings establish 10p as a CHI3L1 inhibitor with a superior pharmacokinetic profile and robust functional activity, marking it as a promising candidate for further GBM drug development.